Seres Therapeutics Inc (MCRB) |
|
8.04 0.26 (3.34%)
|
01-16 05:44 |
|
Open: |
7.68 |
Pre. Close: |
7.78 |
|
High:
|
8.04 |
Low:
|
7.52 |
|
Volume:
|
783,143 |
Market Cap:
|
738M |
|
|
|
|
Seres Therapeutics, Inc., a microbiome therapeutics platform company, engages in developing bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. The company's lead product candidate is the SER-109, an oral microbiome therapeutic candidate that has completed Phase III clinical trial for the treatment of clostridium difficile infection (CDI). It is also developing SER-287 that is in Phase IIb clinical trial to treat ulcerative colitis; SER-401, which is in Phase Ib clinical trial for use with checkpoint inhibitors in patients with metastatic melanoma; and SER-301 that is in the Phase 1b clinical trial for the treatment of inflammatory bowel disease. In addition, the company engages in the development of SER-262 to treat an initial recurrence of CDI; and SER-155, a cultivated bacteria microbiome drug designed to prevent mortality due to gastrointestinal infections, bacteremia, and graft versus host diseases in immunocompromised patients receiving allogeneic hematopoietic stem cell transplantation and solid organ transplants. It has license and collaboration agreements with Nestec Ltd. and Memorial Sloan Kettering Cancer Center. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts. |
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
8.051 - 8.097 |
8.097 - 8.138 |
|
Low:
|
7.405 - 7.462 |
7.462 - 7.514 |
|
Close:
|
7.953 - 8.04 |
8.04 - 8.119 |
|
Technical analysis |
as of: 2022-01-15 8:48:04 PM |
|
Overall:
|
  |
| Stoxline posted a NEUTRAL today, upgraded from lower rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell. |
| Target: |
Six months: 10.68  One year: 11.86 |
| Support: |
Support1: 7.52 Support2: 6.26 |
| Resistance: |
Resistance1: 9.15 Resistance2: 10.15 |
| Pivot: |
8.46 |
| Moving Average: |
MA(5): 8.17 MA(20): 8.51
MA(100): 7.66 MA(250): 14.50 |
| MACD: |
MACD(12,26): -0.20 Signal(9): -0.12 |
| Stochastic oscillator: |
%K(14,3): 11.74 %D(3): 16.30 |
| RSI: |
RSI(14): 43.69 |
| 52-week: |
High: 29.90 Low: 5.41 Change(%): -66.7 |
| Average Vol(K): |
3-Month: 194266 10-Days: 86668 |
|
Price, moving averages and Bollinger Bands |
|
Price and moving averages has closed below its Short term moving average. Short term moving average is currently below mid-term; AND above long term moving averages. From the relationship between price and moving averages; we can see that: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.MCRB has closed above bottom band by 15.9%. Bollinger Bands are 37.9% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Headline News |
Thu, 13 Jan 2022
What You Need To Know About Seres Therapeutics, Inc.'s (NASDAQ:MCRB) Investor Composition - Nasdaq
Tue, 04 Jan 2022
Seres Therapeutics to Present at 40th Annual J.P. Morgan Healthcare Conference - Stockhouse
Mon, 20 Dec 2021
Federated Hermes Kaufmann Fund II Buys GXO Logistics Inc, Seres Therapeutics Inc, Domo Inc, ... - Yahoo Finance
Tue, 26 Oct 2021
Seres Therapeutics Presents Late-Breaking Phase 3 Data on Investigational Microbiome Therapeutic SER-109 in Recurrent C. Difficile Infection at American College of Gastroenterology 2021 Annual Scientific Meeting - Business Wire
Wed, 15 Sep 2021
Why Seres Therapeutics Stock Is Soaring Today - The Motley Fool
Thu, 09 Sep 2021
Seres Therapeutics: Here We Go Again - Seeking Alpha
|
Financial Analysis |
| Growth |
|
| Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing. |
| Profitability |
 |
| Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs. |
| Solvency |
 |
| Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry. |
| Efficiency |
|
| Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not. |
| Price to Book Value: |
Outperform |
Discounted cash flow: |
Outperform |
| Return on Assets: |
Outperform |
Price to Earnings: |
Outperform |
| Return on Equity: |
Outperform |
Debt to Equity: |
Outperform |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. (M) |
|
| Shares Float (M) |
|
|
% Held by Insiders
|
|
|
% Held by Institutions
|
|
|
Shares Short (K)
|
|
|
Shares Short P. Month (K)
|
|
Stock Financials |
|
EPS
|
|
|
EPS Est This Year
|
-2.510 |
|
EPS Est Next Year
|
-2.860 |
|
Book Value (p.s.)
|
|
|
Profit Margin
|
|
|
Operating Margin
|
|
|
Return on Assets (ttm)
|
|
|
Return on Equity (ttm)
|
|
|
Qtrly Rev. Growth
|
|
|
Gross Profit (p.s.)
|
-0.625 |
|
Sales Per Share
|
0.327 |
|
EBITDA (p.s.)
|
-1.367 |
|
Qtrly Earnings Growth
|
|
|
Operating Cash Flow (M)
|
|
|
Levered Free Cash Flow (M)
|
|
Stock Valuations |
|
PE Ratio
|
|
|
PEG Ratio
|
|
|
Price to Book value
|
|
|
Price to Sales
|
24.61 |
|
Price to Cash Flow
|
|
Stock Dividends |
|
Dividend
|
|
|
Forward Dividend
|
|
|
Dividend Yield
|
|
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
7 Binary Options
|
|
Your Ad Here
|
|
